Table 2.
treatment emergent adverse events
| TEAE | All Grades (%) | Grade 1 (%) | Grade 2 (%) | Grade 3 (%) | Grade 4 (%) | Grade 5 (%) |
|---|---|---|---|---|---|---|
| Any | 9 (100%) | 9 (100%) | 9 (100%) | 8 (89%) | 7 (78%) | 1 (11%) |
| IRR | 2 (22%) | 2 (22%) | 0 | 0 | 0 | 0 |
| CRS | 6 (67%) | 6 (67%) | 0 | 0 | 0 | 0 |
| ICANS | 0 | 0 | 0 | 0 | 0 | 0 |
| Infection | 0 | 0 | 0 | 0 | 0 | 0 |
| Pain | 4 (44%) | 2 (22%) | 0 | 2 (22%) | 0 | 0 |
| Fatigue | 8 (89%) | 8 (89%) | 0 | 0 | 0 | 0 |
| Hypotension | 2 (22%) | 0 | 1 (11%) | 1 (11%) | 0 | 0 |
| Headache | 2 (22%) | 2 (22%) | 0 | 0 | 0 | 0 |
| ALT increased | 1 (11%) | 1 (11%) | 0 | 0 | 0 | 0 |
| AST increased | 1 (11%) | 0 | 1 (11%) | 0 | 0 | 0 |
| Anemia | 9 (100%) | 1 (11%) | 5 (56%) | 3 (33%) | 0 | 0 |
| Neutropenia | 8 (89%) | 1 (11%) | 2 (22%) | 0 | 5 (56%) | 0 |
| Thrombocytopenia | 8 (89%) | 3 (33%) | 0 | 1 (11%) | 4 (44%) | 0 |
| Nausea | 6 (67%) | 6 (67%) | 0 | 0 | 0 | 0 |
| Vomiting | 2 (22%) | 2 (22%) | 0 | 0 | 0 | 0 |
| Diarrhea | 2 (22%) | 2 (22%) | 0 | 0 | 0 | 0 |
| Hypocellular marrow | 1 (11%) | 0 | 0 | 0 | 0 | 1 (11%) |
TEAE: Treatment emergent adverse event; IRR: infusion-related reaction; CRS: cytokine release syndrome; ICANS: immune effector cell-associated neurotoxicity syndrome; ALT: alanine transaminase; AST: aspartate transaminase